Table 5.
Incidence rate and hazard ratio (95% confidence interval) of PTDM associated with pretransplant HbA1c≥5.4%
| HbA1c < 5.4% | HbA1c ≥ 5.4% | Overall | |
|---|---|---|---|
| Patients, n | 630 | 869 | 1499 |
| Events | 137 | 258 | 395 |
| Incidence rate, per 100 person-years | 11.07 | 15.85 | 13.78 |
| Unadjusted hazard ratio | 1.0 (reference) | 1.42 (1.15, 1.75) | − |
| Partially adjusted hazard ratio | |||
| Model 1a | 1.0 (reference) | 1.33 (1.07, 1.64) | − |
| Model 2b | 1.0 (reference) | 1.31 (1.06, 1.62) | − |
| Model 3c | 1.0 (reference) | 1.32 (1.07, 1.64) | − |
| Fully adjustedd hazard ratio | 1.0 (reference) | 1.28 (1.03, 1.58) | − |
CMV, cytomegalovirus; HCV, hepatitis C virus; HDL, high-density lipoprotein; HLA, human leukocyte antigen; PTDM, posttransplantation diabetes mellitus; TG, triglyceride.
Model 1: adjusted for age, sex, and race/ethnicity.
Model 2: adjusted for age, sex, race/ethnicity, and components of metabolic syndrome (history of hypertension, body mass index, and serum TG and HDL-cholesterol level).
Model 3: adjusted for all covariates except components of metabolic syndrome in fully adjusted model.
Adjusted for age, sex, race/ethnicity, history of cardiovascular disease, cause of end-stage renal disease, duration of pretransplantation dialysis, year of transplantation, number of prior transplantations, body mass index, history of hypertension, serum TG and HDL-cholesterol level, blood hemoglobin level, erythropoietin use, HLA mismatch, donor type and age, HCV and CMV serostatus, immunosuppressive agents, and time between date of HbA1c measured and date of transplantation.